The FDA released two draft social media guidance documents last week, describing how manufacturers, packers and distributors of prescription drugs and medical devices may: (1) communicate both benefit and risk information on Internet/social media platforms with character space limitations, and (2) correct independent third-party misinformation about a firm’s products. For details, see Reed Smith’s Client
social media
Drug Companies are Reminded – FDA is Following Facebook
By Debra A. McCurdy on
Our Life Sciences Legal Update blog reports today that the FDA’s Office of Prescription Drug Promotion has warned a Swiss drug company about statements the company made on its Facebook page, suggesting that consumers talk to their doctor about a drug without disclosing the risks associated with the product (risks serious enough to require a…
FDA Seeks Comments on Drug Company Social Media Guidance
By Debra A. McCurdy on
As reported on our Life Sciences Legal Update blog, the FDA has issued draft guidance addressing the unique challenges of drug promotion in the age of social media. Specifically, the draft guidance addresses how to submit interactive promotional media for postmarket review. Comments on the document, “Draft Guidance for Industry on Fulfilling Regulatory…